Prelude Therapeutics Inc

Prelude Therapeutics Inc (PRLD) priced its initial public offering on Sep 25, 2020 at $19.00 per share, within its $17.00–$19.00 range, raising $158.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $806.6M. Goldman Sachs was lead-left underwriter. Fenwick & West advised the company and Cooley advised the underwriters.

Prelude Therapeutics Inc is a clinical-stage precision oncology company discovering and developing small molecule therapies against key driver mechanisms in cancers with high unmet need. Since its 2016 inception it has received FDA clearance for three investigational new drug applications from its internally developed pipeline.

Status

IPO

Ticker

PRLD

Exchange

Nasdaq Global Select

Priced

Sep 25, 2020

IPO price

$19.00

Price range

$17.00–$19.00

Raised

$158.2M

Market cap at IPO price

$806.6M

First filed

Sep 4, 2020

Underwriters

Goldman Sachs

Company counsel

Fenwick & West

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

DE

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.